Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6602667
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Gemcitabine Plus Vinorelbine as First-Line Chemotherapy in Advanced Nonsmall Cell Lung Carcinoma a Phase II Trial

Cancer
Cancer ResearchOncology
2000English

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2009English

Gemcitabine Plus Vinorelbine in Advanced Non-Small Cell Lung Cancer: A Phase II Study of Three Different Doses

British Journal of Cancer
Cancer ResearchOncology
2000English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

A Phase I Study of Imexon Plus Gemcitabine as First-Line Therapy for Advanced Pancreatic Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel as First-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancers

Archives of Medical Science
Medicine
2014English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer

BMJ
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy